Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 13/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14758456 | 0.92 | KMO (0.66) | KMODYRK1AEGLN2CYP1A1CYP1B1 | |
| SCHEMBL18651048 | 0.85 | KMO (0.62) | KMODYRK1AEGLN2MEN1KMT2A | |
| SCHEMBL14741878 | 0.84 | KMO (1.00) | KMO | |
| SCHEMBL18058379 | 0.83 | KMO (0.79) | KMO | |
| SCHEMBL4302847 | 0.80 | DYRK1A (0.65) | KMODYRK1AEGLN2MEN1KMT2A | |
| SCHEMBL21290152 | 0.80 | DYRK1A (0.57) | KMODYRK1AEGLN2MEN1KMT2A | |
| SCHEMBL10684909 | 0.79 | KMO (0.52) | KMODYRK1AMEN1KMT2AL3MBTL1 | |
| SCHEMBL21289970 | 0.78 | DYRK1A (0.55) | KMODYRK1AEGLN2MEN1KMT2A | |
| SCHEMBL21290390 | 0.78 | NPC1 (0.63) | KMODYRK1AEGLN2MEN1KMT2A | |
| SCHEMBL21290163 | 0.77 | KMO (0.50) | KMODYRK1AEGLN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271989-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-08-31 | — | — | US | disclosed |
| WO-2022034046-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271989-A1 | METAL COMPLEXES | AP3M1, AP1M1, AP2M1 | KMO 1575/4885DYRK1A 3622/4885EGLN2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.